**Core Concept**
P. jirovecii, also known as Pneumocystis jirovecii, is a fungus that causes Pneumocystis pneumonia (PCP) primarily in immunocompromised patients, such as those with HIV/AIDS. The drug of choice (DOC) for treating PCP is a key concept in managing this opportunistic infection.

**Why the Correct Answer is Right**
Cotrimoxazole, a combination of trimethoprim and sulfamethoxazole, is the recommended treatment for P. jirovecii pneumonia. This is because trimethoprim inhibits dihydrofolate reductase, an enzyme essential for the synthesis of tetrahydrofolate, which is necessary for DNA synthesis and cell replication in the fungus. Sulfamethoxazole, on the other hand, inhibits dihydropteroate synthase, another enzyme required for tetrahydrofolate synthesis. By combining these two drugs, cotrimoxazole effectively targets the folate metabolism pathway in P. jirovecii, leading to its inhibition and subsequent death.

**Why Each Wrong Option is Incorrect**
**Option A:** Clotrimazole is an antifungal agent, but it is primarily used to treat dermatophyte infections such as athlete's foot and ringworm. It is not effective against P. jirovecii.
**Option C:** Penicillin is a beta-lactam antibiotic that targets bacterial cell wall synthesis, making it ineffective against P. jirovecii, a fungus that lacks a cell wall.

**Clinical Pearl / High-Yield Fact**
It is essential to note that cotrimoxazole is not only the treatment of choice for PCP but also serves as primary prophylaxis in HIV/AIDS patients with a CD4 count below 200 cells/μL to prevent the onset of PCP.

**Correct Answer:**
✓ Correct Answer: B. Cotrimoxazole